Tag: Shilpa Medicare

Shilpa Medicare has received an import alert 66-40 on February 17, 2021, pursuant to the USFDA inspection of the Unit IV, Jadcherla,...

NEW DELHI: The US Food and Drug Administration (USFDA) has issued a warning letter to Shilpa Medicare for violating current good manufacturing practice norms...

Shilpa Medicare has received a warning letter through email from the USFDA for its Jadcherla facility, Telangana. The company...

Shilpa Medicare announced the launch of the Indian branded generic of lbrutinib, an anti-cancer drug under the brand name IBRUSHIL. Earlier it...

Shilpa Medicare Limited (SML) has announced the receipt of Establishment Inspection Report (EIR) from the US Food and Drug Administration (FDA) for...

Shilpa Medicare has received 15 observations from US Food and Drug Administration (FDA) for the company's finished dosage formulation facility (sterile...